Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Key facts

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Principal Investigator

Christine H. Chung, M.D., MD

H. Lee Moffitt Cancer Center and Research Institute

Intervention

Nivolumab(drug)

Enrollment

95 enrolled

Eligibility

18 years · All sexes

Timeline

2017 – 2023

Study locations (3)

• H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
• Emory University School of Medicine, Atlanta, Georgia, United States
• The Ohio State University, Columbus, Ohio, United States

Collaborators

James and Esther King Biomedical Research Program · Eli Lilly and Company · Bristol-Myers Squibb

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Squamous cell carcinoma of the hypopharynx

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07063212
  A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
  Memorial Sloan Kettering Cancer Center
• RECRUITINGPHASE1NCT06761937
  Thermoradiotherapy for Locally Advanced Head and Neck Cancer Patients
  Erasmus Medical Center
• RECRUITINGPHASE3NCT06706401
  Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma
  Centre Leon Berard
• RECRUITINGNCT06380686
  Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome
  AIO-Studien-gGmbH
• RECRUITINGPHASE3NCT06525220
  A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
  Merus B.V.
• RECRUITINGPHASE3NCT05333523
  Personalized Elective Neck Irradiation Guided by Sentinel Lymph Node Biopsy in Larynx and Pharynx Cancer. The PRIMO Study.
  Radboud University Medical Center
• RECRUITINGPHASE2NCT04858269
  First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients
  Wake Forest University Health Sciences
• ACTIVE NOT RECRUITINGPHASE3NCT04590963
  Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer
  AstraZeneca

See all trials for Squamous cell carcinoma of the hypopharynx →